Summit Therapeutics (SMMT) Net Equity Issued and Repurchased (2019 - 2025)

Summit Therapeutics (SMMT) has reported Net Equity Issued and Repurchased for 6 consecutive years, with $468.3 million the latest figure, recorded in Q4 2025.

• Quarterly Net Equity Issued and Repurchased rose 11706925.0% year-over-year to $468.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $543.1 million (up 1161.98% YoY) and the FY2025 annual result came in at $500.0 million, up 1061.98% from the prior year.
• Net Equity Issued and Repurchased grew to $468.3 million in Q4 2025 per SMMT's latest filing, from $31.8 million in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for SMMT reached as high as $468.3 million in Q4 2025 and fell as low as -$619000.0 in Q3 2023.
• A 4-year average of $93.5 million and a median of $37.4 million in 2024 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2024 — Net Equity Issued and Repurchased plunged 100.65% — and 2025, when it surged 11706925.0%.
• Year by year, Net Equity Issued and Repurchased stood at $100.0 million in 2022, then sank by 99.38% to $619000.0 in 2023, then plunged by 100.65% to -$4000.0 in 2024, then jumped by 11706925.0% to $468.3 million in 2025.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $468.3 million, $31.8 million, and -$4000.0 for Q4 2025, Q3 2025, and Q4 2024 respectively.